Ozmosi | Cefoxitin Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Cefoxitin

Alternative Names: cefoxitin, cefoxitina, mefoxin, mefoxin in plastic container
Clinical Status: Inactive
Latest Update: 2025-10-21
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Cell Wall Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous, Intramuscular, Oral

FDA Designation: *

Approval Status: Approved

Approved Countries: Argentina | Australia | Bangladesh | Brazil | Canada | Chile | China | Colombia | Egypt | Estonia | France | Germany | Greece | Ireland | Italy | Jordan | Korea | Lebanon | New Zealand | Pakistan | Peru | Philippines | Portugal | Russia | Saudi Arabia | Slovenia | South Africa | Spain | Taiwan | Thailand | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: CHU DE POITIERS
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

2022-003262-20

2022-003262-20

P3

Active, not recruiting

Unknown

2026-01-19

Recent News Events

Date

Type

Title